EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women

Bilal Chughtai, James C Forde, Jessica Buck, Tirsit Asfaw, Richard Lee, Alexis E Te, Steven A Kaplan

Post Reproductive Health · 2016-03 · 22 (1) · 34-40

DOI: 10.1177/2053369116633017 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Post Reproductive Health, online erschienen am 16.02.2016. Verfasst von Bilal Chughtai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Weill Cornell Medical College/New York Presbyterian Hospital, NY, USA bic9008@med.cornell.edu. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study is to investigate the combination effect of anti-muscarinic medication and topical vaginal estrogen in the treatment of overactive bladder (OAB) and female sexual dysfunction in postmenopausal women. Study design After IRB approval, 23 female subjects who met the entry criteria were randomized into two groups: (1) fesoterodine (Toviaz®, Pfizer, NY) with topical vaginal estrogen (Premarin®, Pfizer, NY) once daily or (2) fesoterodine once daily alone. If 4 mg fesoterodine was tolerated at 1-week, the dose was increased to 8 mg. Main outcome measures Primary endpoints were improvement in OAB symptom severity (Overactive Bladder Questionnaire, OAB-Q SF), improvement in OAB health-related quality of life (HRQL) (OAB-Q SF), and sexual function (Sexual Quality of Life–Female, SQOL-F) after 12 weeks. Secondary endpoint was change in total number of micturitions.

Results

After 12-weeks, the combination group had a significant improvement in OAB symptom severity ( p = 0.006), HRQL ( p = 0.029), and SQOL-F (0.0003). The fesoterodine alone group also had significant improvement in OAB symptom severity ( p < 0.0001), HRQL ( p = 0.0002), and SQOL-F ( p = 0.02). When compared directly to the fesoterodine alone group, the combination group after 12-weeks had a reduced OAB symptom severity (10 versus 23.3; p = 0.35), higher HRQL (96.9 versus 84.6; p = 0.75), and higher SQOL-F (99 versus 81; p = 0.098). The total number of micturitions over 3 d was significantly reduced in the combination group (45–26, p = 0.03) between baseline and 12-weeks.

Conclusions

The combined effect of fesoterodine and topical vaginal estrogen improved OAB symptoms and sexual function in postmenopausal women.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Administration, IntravaginalAdultAgedBenzhydryl CompoundsDrug Therapy, CombinationEstrogensFemaleHumansMiddle AgedMuscarinic AntagonistsPostmenopauseQuality of LifeSeverity of Illness IndexSexual Dysfunctions, PsychologicalSexualitySurveys and QuestionnairesUrinary Bladder, Overactive

Stichwörter der Autor:innen

Overactive bladderfemale sexual dysfunctionfesoterodinepostmenopausaltopical vaginal estrogen

Substanzen

Benzhydryl CompoundsEstrogensMuscarinic Antagonistsfesoterodine

Autor:innen und Institutionen

  • Department of Urology, Weill Cornell Medical College/New York Presbyterian Hospital, NY, USA bic9008@med.cornell.edu.
  • Department of Urology, Weill Cornell Medical College/New York Presbyterian Hospital, NY, USA.
  • Department of Obstetrics and Gynecology, Weill Cornell Medical College/New York Presbyterian Hospital, NY, USA.

Zitieren

APA

Chughtai, B., Forde, J. C., Buck, J., Asfaw, T., Lee, R., Te, A. E., & Kaplan, S. A. (2016). The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women. Post Reproductive Health, 22(1), 34-40. https://doi.org/10.1177/2053369116633017

Vancouver

Chughtai B, Forde JC, Buck J, Asfaw T, Lee R, Te AE, et al. The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women. Post Reproductive Health. 2016;22(1):34-40. doi:10.1177/2053369116633017

BibTeX
@article{Chughtai2016,
  author = {Chughtai, Bilal and Forde, James C and Buck, Jessica and Asfaw, Tirsit and Lee, Richard and Te, Alexis E and Kaplan, Steven A},
  title = {The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women},
  journal = {Post Reproductive Health},
  year = {2016},
  volume = {22},
  number = {1},
  pages = {34--40},
  doi = {10.1177/2053369116633017}
}
Kostenlos starten →